Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dai-saiko-to
- Development stage
- Unknown
- Lead developer
- Tsumura
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dai-saiko-to (Da-Chai-Hu-Tang) is a traditional Kampo (Japanese-Chinese) herbal medicine composed of eight crude drugs: Bupleurum root, Scutellaria root, Rhubarb, Peony root, Immature Orange, Ginger, Jujube, and Pinellia tuber. It is primarily used to treat liver and gallbladder disorders, gastrointestinal issues, and metabolic conditions such as hyperlipidemia and obesity. Its pharmacological actions include the inhibition of gastric H+/K+-ATPase and phosphodiesterase (PDE) enzymes, modulation of lipid metabolism through increased LDL-receptor expression, and decreased triglyceride biosynthesis. It also exhibits antioxidant properties and can influence hepatic drug-metabolizing enzymes by inducing several Cytochrome P450 isoforms. While generally considered safe and widely used in Japan, it has been associated with rare adverse events such as interstitial pneumonia and drug-induced liver injury.
- Brand names
- Dai-saiko-to
- Other names
- Da-Chai-Hu-TangMajor Bupleurum Combination
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)LDLR (Low-density lipoprotein receptor)PNLIP (Pancreatic triacylglycerol lipase)ATP4A (Potassium–transporting ATPase alpha chain 1)PDE (Phosphodiesterase family)
Beyond the preview
Go deeper on dai-saiko-to.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dai-saiko-to.